Clinical Trials
8
0 active
Approvals
0
Total approvals
Agencies
0
Regulatory bodies
Founded
1929
Completed
6
75.0%
Terminated
2
25.0%
No approval data available
- Curi Bio unveiled the Curiverse™ at MPS 2026, the industry's first closed-loop ecosystem integrating iPSC-derived cells, automated systems, and cloud analytics for industrial-scale 3D human drug discovery. - The platform scales to 96-well throughput with three integrated pillars: assay-ready patient-specific cells, automated biosystems including Nautilai Plus™, and Pulse™ analytical engine for standardized data extraction. - The launch addresses regulatory shifts toward Non-Animal Models following FDA Modernization Act 2.0, breaking scalability bottlenecks that previously confined complex 3D tissue models to boutique workflows. - Curi Bio's strategic partnership with Battelle aims to commercialize neuromuscular junction assay technology, combining innovative microphysiological systems with GLP-ready infrastructure for human-relevant alternatives to animal bioassays.
- Spark Biomedical has been awarded a $318,875 SBIR grant from the National Institute on Drug Abuse (NIDA) to develop an AI algorithm for detecting opioid withdrawal symptoms and cravings. - The AI algorithm will analyze data from wearable devices that measure digital and physical biomarkers, along with clinical assessments, to proactively identify withdrawal symptoms. - The second phase of the project will apply the AI algorithm to trigger closed-loop neurostimulation using Spark Biomedical’s Sparrow Ascent device for timely intervention. - The collaboration with Battelle Memorial Institute and Hazelden Betty Ford Foundation aims to improve treatment effectiveness, patient compliance, and reduce relapse rates in opioid use disorder (OUD) recovery.
- Janssen's Head of Combination Products Center of Excellence, Susan Neadle, will deliver a keynote presentation on drug-device combination product development challenges at the Pre-Filled Syringes East Coast Conference in Boston. - The conference will feature critical discussions on manufacturing processes, including high-concentration monoclonal antibody formulation filling and technical updates from industry leaders GSK and ZEON. - Interactive workshops focusing on design considerations and human factors for connected drug delivery systems will be led by experts from Battelle and Cambridge Consultants Ltd.
